5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis

K. Forrest, John; J. Yakubov, Steven; Michael Deeb, G.; Gada, Hemal; Mumtaz, Mubashir; Ramlawi, Basel; Bajwa, Tanvir; Crouch, John; Merhi, William; Leung Wai Sang, Stephane; S. Kleiman, Neal; Petrossian, George; Bryce Robinson, N.; Sorajja, Paul; Iskander, Ayman; Berthoumieu, Pierre; Tchétché, Didier; M. Feindel, Christopher; Horlick, Eric; Saito, Shigeru; K. Oh, Jae; Jung, Yoojin; J. Reardon, Michael

doi:10.1016/j.jacc.2025.03.004

Public

5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis

Published in Journal of the American College of Cardiology • Apr 1, 2025

Authors:

John K. Forrest

Steven J. Yakubov

G. Michael Deeb

Abstract

BACKGROUND: The Evolut Low Risk trial demonstrated that transcatheter aortic valve replacement (TAVR) was noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at 2 years. Outcomes at 5 years have not been reported. OBJECTIVES: This study sought to evaluate 5-yea...

Subject

Medicine

Stenosis

Cardiology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!